MindWalk (NASDAQ:HYFT) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of MindWalk (NASDAQ:HYFT) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other brokerages have also recently weighed in on HYFT. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, JonesTrading started coverage on shares of MindWalk in a research note on Thursday, April 16th. They issued a “buy” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MindWalk has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

MindWalk Stock Performance

Shares of NASDAQ HYFT opened at $1.36 on Friday. The firm has a 50 day moving average price of $1.56. MindWalk has a 52 week low of $0.99 and a 52 week high of $3.25. The company has a market cap of $63.53 million, a PE ratio of -6.18 and a beta of 0.83. The company has a current ratio of 2.80, a quick ratio of 3.64 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $3.03 million during the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. On average, analysts predict that MindWalk will post -0.21 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in MindWalk by 8.4% during the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares in the last quarter. Virtu Financial LLC bought a new position in shares of MindWalk during the 4th quarter worth approximately $51,000. XTX Topco Ltd lifted its position in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after buying an additional 44,331 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in shares of MindWalk during the 4th quarter worth approximately $91,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

MindWalk News Summary

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on MindWalk, and brokerage sentiment remains at Moderate Buy, which can support investor confidence. MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company’s recent earnings-call coverage focused on its growth strategy despite continued losses, reinforcing the view that investors are weighing long-term potential against near-term unprofitability. MindWalk Holdings Charts Growth Amid Persistent Losses
• Negative Sentiment: HC Wainwright cut multiple earnings estimates for MindWalk across 2027-2030, including lowering FY2027 EPS to ($0.21) and trimming FY2028, FY2029, and FY2030 forecasts, signaling a more cautious outlook for future profitability. MindWalk (NASDAQ:HYFT) Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: The latest quarterly results missed estimates, with EPS of ($0.06) versus expectations for ($0.05), underscoring ongoing losses even as revenue came in at $3.03 million.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.